The average relapsed cancer patient’s tumor will be resistant to at least 4 different therapies.
Creative BioTherapeutics was created to treat patients with incurable cancers. There are no current therapies that can permanently eliminate therapy resistant brain and metastatic cancers.
Children with brain cancer are not expected to live past a year.
Most patients with lung and metastatic breast cancers have a 5-year survival rate of less than 25%.
The list of uphill battles is constant. Through our innovations in biotech, we are dedicated to the discovery of non-toxic, novel therapies to give hope to patients. By releasing the immune system and attacking tumors directly, we discover and develop first in class drugs to target treatment resistant cancers.
We treat cancer as a wound that won’t heal.
Our therapies heal the wound.
By discovering how these cells are able to survive, we can reverse and relieve drug resistance and immune avoidance. We leverage the power of late stage, metastatic, highly resistant tumor cells to discover and develop drugs that will block tumor escape pathways created by chemotherapies.
Reverses Resistance
Our anti-cancer treatments reverse drug resistance for late stage metastatic cancers. By blocking survival pathways the tumors are forced to regress. As of today, no resistance to our therapies has been observed in our breast cancer.
Prevents Immune Weakening
The inhibition of these survival pathways also prevent the tumor cell from weakening the immune system. Traditional chemotherapies attack the immune system as well as the tumor. Our drug allows the immune system to attack the tumor itself.
Safe and Effective
By attacking survival pathways, our drugs are not toxic to normal cells. Currently, these inhibitors are effective against metastatic breast cancer, adult and pediatric brain cancers, colon cancer, metastatic lung and ovarian cancer.
CBT300 kills drug resistant breast cancer cells, not normal cells.
Creative BioTherapeutics' lead escape pathway inhibitor, CBT300, can selectively kill drug resistant, metastatic breast cancer cells but not normal breast cells.
We have discovered an escape pathway in drug resistant, metastatic breast tumor cells that is not present in normal cells. By exploring this pathway, we have designed and patented novel drugs that block this unique mechanism. Our lead drug, CBT300, causes drug resistant breast cancer tumor cell death much more effectively than the cytotoxic drug, Doxorubicin. However, CBT300 is safe against normal breast cells, whereas Doxorubicin is not.
CBT300 prevents immune cell deactivation and stimulates immune cell activation. When CBT300 blocks the unique escape route that results in activation of the immune cells. With the increased activation of immune cells, tumor regressions and patient survival will be greatly improved.
COVID-19 is blocked by CBT300
For the millions of people living with lung cancer, who because of this comorbidity have a much higher risk of being infected and dying from COVID-19, our inhibitor, CBT300, provides an innovative, safe, low-cost and effective therapy to prevent virus infection and patient death. Our research shows that survival pathways, up regulated in lung cancer cells, increase the COVID-19 co-receptor stress protein that is essential for COVID-19 virus infectivity. Used as a stand-alone therapy or in combination with other virus inhibitors, CBT300 will greatly improve the outcomes for late stage COVID-19.